Embecta (EMBC) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Embecta Revenue Highlights


Latest Revenue (Y)

$1.12B

Latest Revenue (Q)

$272.50M

Main Geography (Y)

UNITED STATES

Embecta Revenue by Period


Embecta Revenue by Year

DateRevenueChange
2023-09-30$1.12B-0.77%
2022-09-30$1.13B-3.05%
2021-09-30$1.17B7.32%
2020-09-30$1.09B-2.12%
2019-09-30$1.11B-

Embecta generated $1.12B in revenue during NA 2023, up -0.77% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Embecta Revenue by Quarter

DateRevenueChange
2024-06-30$272.50M-5.12%
2024-03-31$287.20M3.57%
2023-12-31$277.30M-1.63%
2023-09-30$281.90M-1.47%
2023-06-30$286.10M3.25%
2023-03-31$277.10M0.51%
2022-12-31$275.70M0.40%
2022-09-30$274.60M-5.67%
2022-06-30$291.10M6.05%
2022-03-31$274.50M-5.12%
2021-12-31$289.30M-3.73%
2021-09-30$300.50M1.86%
2021-06-30$295.00M3.80%
2021-03-31$284.20M-0.39%
2020-12-31$285.30M51.11%
1968-12-31$188.80M-

Embecta generated $272.50M in revenue during Q3 2024, up -5.12% compared to the previous quarter, and up 98.34% compared to the same period a year ago.

Embecta Revenue Breakdown


Embecta Revenue Breakdown by Country

Annual Revenue by Country

CountrySep 23Sep 22
UNITED STATES$601.40M$600.30M
Non-US$519.40M$529.20M

Embecta's latest annual revenue breakdown by geography, as of Sep 23: UNITED STATES (53.66%), and Non-US (46.34%).

Quarterly Revenue by Country

CountryMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21
UNITED STATES$147.60M$148.60M$151.80M$153.90M$146.40M$149.30M$149.90M$158.00M$139.80M-
Non-US$139.60M$128.70M$130.10M$132.20M$130.70M$126.40M$124.70M$133.10M$134.70M$138.40M
United States of America, Dollars---------$150.90M

Embecta's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (51.39%), and Non-US (48.61%).

Embecta Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
BAXBaxter$14.81B$3.59B
ALCAlcon$10.09B$2.46B
RMDResMed$4.69B$1.22B
COOCooper Companies$3.59B$1.00B
ATRAptarGroup$3.49B$909.29M
TFXTeleflex$2.97B$764.38M
WSTWest Pharmaceutical Services$2.95B$746.90M
NVSTEnvista$2.57B$884.70M
ICUIICU Medical$2.26B$596.46M
HAEHaemonetics$1.31B$336.17M
MMSIMerit Medical Systems$1.26B$339.85M
EMBCEmbecta$1.12B$272.50M
ATRCAtriCure$399.25M$115.91M
ANGOAngioDynamics$303.91M$67.49M
AKYAAkoya Biosciences$96.63M$23.16M
ATRIAtrion-$48.77M

EMBC Revenue FAQ


Embecta's yearly revenue for 2023 was $1.12B, representing a decrease of -0.77% compared to 2022. The company's yearly revenue for 2022 was $1.13B, representing a decrease of -3.05% compared to 2021. EMBC's yearly revenue for 2021 was $1.16B, representing an increase of 7.32% compared to 2020.

Embecta's quarterly revenue for Q3 2024 was $272.5M, a -5.12% decrease from the previous quarter (Q2 2024), and a -4.75% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $287.2M, a 3.57% increase from the previous quarter (Q1 2024), and a 3.64% increase year-over-year (Q2 2023). EMBC's quarterly revenue for Q1 2024 was $277.3M, a -1.63% decrease from the previous quarter (Q4 2023), and a 0.58% increase year-over-year (Q1 2023).

Embecta's revenue growth rate for the last 3 years (2021-2023) was -3.79%, and for the last 5 years (2019-2023) was 1.06%.